Portal de Periódicos da CAPES

Zinc and zinc transporters in prostate carcinogenesis

2013; Nature Portfolio; Volume: 10; Issue: 4 Linguagem: Inglês

10.1038/nrurol.2013.43

1759-4820

Vladimir Kolenko, Ervin Teper, Alexander Kutikov, Robert G. Uzzo,

Iron Metabolism and Disorders

Kolenko et al. consider the evidence supporting a role for zinc in prostate carcinogenesis and discuss how a better understanding of the mechanisms of zinc homeostasis could be used to improve diagnosis and treatment of men with prostate cancer. The healthy human prostate accumulates the highest level of zinc of any soft tissue in the body. This unique property is retained in BPH, but is lost in prostatic malignancy, which implicates changes in zinc and its transporters in carcinogenesis. Indeed, zinc concentrations diminish early in the course of prostate carcinogenesis, preceding histopathological changes, and continue to decline during progression toward castration-resistant disease. Numerous studies suggest that increased zinc intake might protect against progression of prostatic malignancy. In spite of increased dietary intake, zinc accumulation might be limited by the diminished expression of zinc uptake transporters, resulting in decreased intratumoural zinc levels. This finding can explain the conflicting results of various epidemiological studies evaluating the role of zinc supplementation on primary and secondary prostate cancer prevention. Overall, more research into the mechanisms of zinc homeostasis are needed to fully understand its impact on prostate carcinogenesis. Only then can the potential of zinc and zinc transport proteins be harnessed in the diagnosis and treatment of men with prostate cancer.